Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIRON: ATL001 in Advanced NSCLC
NCT04032847Phase 2Terminated
- Sponsor
- Achilles Therapeutics plc
- Start
- Jul 2019
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Native Immune Cells
- Countries
- 5
01
Overview
A Phase 2 trial of ATL001 in non-small cell lung cancer (NSCLC), sponsored by Achilles Therapeutics plc. Started Jul 2019; status: terminated.
02
Drugs
ATL001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04032847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032847.